|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1650 Diagonal Road |
Address2 |
|
| City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1386-12
|
||||||||
|
6. House ID# 321810000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Jonah Scharf |
Date | 7/20/2023 12:43:23 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
April 7, 2023 coalition letter to HHS Deputy Assistance Secretary for the Office of Human Services Policy Miranda Lynch-Smith in response to their Request for Input (RFI) pertaining to improving care delivery and integrating specialty care in population-based models.
April 24, 2023 coalition letter to Representatives Bucshon and Ruiz in support of their legislation H.R. 5239, the Good Samaritan Health Professionals Act of 2023, which would ensure that victims of federally declared disasters and public health emergencies have adequate access to medical care following a catastrophic event while protecting healthcare workers and volunteers.
May 3, 2023 coalition letter to Senators Lisa Murkowski, Roger Marshall, Maggie Hassan, and Jacky Rosen in support of S. 652, the Safe Step Act, which would provide patients and providers with a clear and transparent appeals process when subject to step therapy protocols instituted by insurers.
May 3, 2023 coalition letter to Representatives Brad Wenstrup and Raul Ruiz in support of H.R. 2630, The Safe Step Act, which would provide patients and providers with a clear and transparent appeals process when subject to step therapy protocols instituted by insurers.
May 3, 2023 coalition letter to Representatives Raul Ruiz, Ami Bera, Larry Bucshon, and Marianette Miller-Meeks in support of their legislation H.R. 2474, The Strengthening Medicare for Patients and Providers Act, which would provide an annual inflationary update for Medicare physician payment tied to the Medicare Economic Index (MEI).
May 3, 2023 coalition letter to Senators Bob Menendez, Chuck Schumer, John Boozman, and Susan Collins in support of their legislation S. 1302, the Resident Physician Shortage Reduction Act of 2023, which would increase the number of Graduate Medical Education residency positions in order to tackle the severe physician shortage.
May 5, 2023 letter to the HHS Director of the Hospital and Ambulatory Policy Group Carol Blackford to request clarification on whether outpatient telehealth services provided to Medicare beneficiaries by facility-based speech-language pathologists (SLPs) will be covered after the end of the federally declared public health emergency (PHE) on May 11, 2023.
May 8, 2023 coalition letter to Representatives Terri Sewell and Brian Fitzpatrick in support of their legislation H.R. 2389, the Resident Physician Shortage Reduction Act of 2023, which would increase the number of Graduate Medical Education residency positions in order to tackle the severe physician shortage.
May 22, 2023 coalition letter to Senators Bob Menendez, Chuck Schumer, John Boozman, and Susan Collins in support of their legislation S. 1302, the Resident Physician Shortage Reduction Act of 2023, which would increase the number of Graduate Medical Education residency positions in order to tackle the severe physician shortage.
May 23, 2023 coalition letter to Senators Richard Blumenthal, Gary Peters, Ron Johnson, and Rand Paul thanking them for their hearing examining health care denials and delays in Medicare Advantage particularly pertaining to the issues of prior authorization and utilization management.
June 12, 2023 coalition letter to Representatives Kay Granger and Rosa DeLauro urging them to reject any efforts to narrow, weaken, or modify the Food and Drug Administrations current authority to oversee tobacco products during consideration of the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill.
June 20, 2023 coalition letter to National Coordinator for Health Information Technology Micky Tripathi providing feedback on issues pertaining to ONCs HT-1 proposed rule, development of CEHRT criteria, and prior authorization requirements.
Issues pertaining to scope of practice legislation, in general.
Issues pertaining to prior authorization, in general.
Issues pertaining to Medicare physician reimbursement, related to H.R. 2474, and in general.
Issues related to hearing healthcare, in general.
Issues pertaining to health information technology and electronic health records, in general.
Issues pertaining to Graduate Medical Education, in general.
Issues pertaining to healthcare liability reform, in general.
Issues pertaining to healthcare practice and the Federal Supremacy Clause at the Department of Veterans Affairs, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Federal Trade Commission (FTC), Centers For Medicare and Medicaid Services (CMS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
May 3, 2023 coalition letter to Representatives Raul Ruiz, Ami Bera, Larry Bucshon, and Marianette Miller-Meeks in support of their legislation H.R. 2474, The Strengthening Medicare for Patients and Providers Act, which would provide an annual inflationary update for Medicare physician payment tied to the Medicare Economic Index (MEI).
May 5, 2023 letter to the HHS Director of the Hospital and Ambulatory Policy Group Carol Blackford to request clarification on whether outpatient telehealth services provided to Medicare beneficiaries by facility-based speech-language pathologists (SLPs) will be covered after the end of the federally declared public health emergency (PHE) on May 11, 2023.
May 23, 2023 coalition letter to Senators Richard Blumenthal, Gary Peters, Ron Johnson, and Rand Paul thanking them for their hearing examining health care denials and delays in Medicare Advantage particularly pertaining to the issues of prior authorization and utilization management.
Issues pertaining to scope of practice legislation, in general.
Issues pertaining to prior authorization, in general.
Issues pertaining to Medicare physician reimbursement, related to H.R. 2474, and in general.
Issues related to hearing healthcare, in general.
Issues pertaining to health information technology and electronic health records, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
June 12, 2023 coalition letter to Representatives Kay Granger and Rosa DeLauro urging them to reject any efforts to narrow, weaken, or modify the Food and Drug Administrations current authority to oversee tobacco products during consideration of the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill.
Issues pertaining to tobacco control, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Issues pertaining to healthcare practice and the Federal Supremacy Clause at the Department of Veterans Affairs, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
June 12, 2023 coalition letter to Representatives Kay Granger and Rosa DeLauro urging them to reject any efforts to narrow, weaken, or modify the Food and Drug Administrations current authority to oversee tobacco products during consideration of the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |